Info

AquaGene makes human therapeutic proteins in genetically engineered ("transgenic") fish. The company's first product, human coagulation Factor VII, will be ready in 2001. A 'platform' technology: Although we will make our own products, our primary strategy is to provide protein therapeutics to other biotechs and pharmaceutical companies. The fish bioreactor: Our tilapia breed rapidly. As vertebrates, they create proteins that are correctly structured and post-translationally modified. The technology is more easily scalable than large animals or cell culture. Thus, fish are an ideal production system for a variety of complex human proteins. The need: Mapping the genome accelerates the need for therapeutic proteins. The existing market is $29.4 billion, and it's growing rapidly.